Core Viewpoint - The article highlights the upcoming listing of Jianfa Zhixin Medical Technology Group Co., Ltd. on the Shenzhen Stock Exchange, emphasizing its role as a state-owned enterprise and a national high-value medical device distributor, focusing on direct sales and distribution, as well as providing centralized operation services for medical consumables [1]. Industry Overview - The medical device market is experiencing continuous growth driven by factors such as an aging population, rising chronic disease rates, and improved health awareness among residents [2]. - Despite the promising outlook, the medical device distribution sector faces significant challenges, including a fragmented supply chain, low operational efficiency, and issues with product identification and data standardization [2][3]. Company Innovations - Jianfa Zhixin is innovating through a "national integrated medical device distribution hub" model, which aims to improve management costs and efficiency while addressing traceability issues in the distribution of medical consumables [4][5]. - The company has developed a centralized management system for medical consumables, enhancing operational efficiency and reducing human resource demands through automation and smart technology [5][7]. Market Position and Growth - Jianfa Zhixin has strategically positioned itself in the high-value medical consumables market, achieving significant growth with contracts signed for centralized operation services with 60 hospitals, managing over 10 billion yuan in medical consumables [9]. - The company has reported impressive revenue growth, with projected revenues of 118.82 billion yuan in 2022, 154.43 billion yuan in 2023, and 179.23 billion yuan in 2024, reflecting a compound annual growth rate of 22.81% from 2022 to 2024 [9][10]. Competitive Advantage - Jianfa Zhixin's innovative solutions and operational efficiency have positioned it as a leader in the medical device distribution industry, with the highest revenue growth rate among major competitors [10][11]. - The company's focus on addressing industry pain points through its integrated distribution model and advanced supply chain management systems has garnered market recognition and facilitated rapid project implementation [11].

Core Viewpoint - The company, Jianfa Zhixin, is set to go public with an IPO of over 63 million shares, aiming to leverage its strong growth in the high-value medical device distribution sector, which is experiencing intense competition and market consolidation [1]. Group 1: Company Overview - Jianfa Zhixin plans to issue 63.19 million shares with a price-earnings ratio of 13.29, lower than the industry average of 25.73 [1]. - The company reported revenues of 11.882 billion, 15.443 billion, and 17.923 billion yuan for 2022 to 2024, with a compound annual growth rate (CAGR) of 22.81% [1]. - The net profit attributable to the parent company for the same period is projected to be 169 million, 191 million, and 224 million yuan, with a CAGR of 14.99% [1]. Group 2: Industry Challenges and Innovations - The medical device distribution sector faces challenges due to the complexity of products and high-frequency, small-batch delivery requirements, necessitating higher professional standards [2]. - Jianfa Zhixin focuses on addressing core pain points in the medical device supply chain through innovations such as a national integrated distribution hub and modern technology applications [2][3]. - The company has developed a digital supply chain management system and a specialized information management system for medical devices, enhancing compliance, accuracy, traceability, and safety [2]. Group 3: Operational Efficiency and Market Reach - The company has established a unified management system for its warehouses and subsidiaries, improving information flow and operational efficiency across the supply chain [3]. - Jianfa Zhixin collaborates with over 100 well-known medical device manufacturers and serves more than 3,300 medical institutions across 31 provinces, including over 1,600 tertiary hospitals [4]. Group 4: SPD Model and Market Potential - The company has implemented the SPD (Supply Chain Management) model, which enhances management efficiency and supports the digital transformation of the medical device industry [5][6]. - As of Q3 2023, approximately 1,800 medical institutions have adopted the SPD model, with a penetration rate of 15.29% in public hospitals, indicating significant future market potential [5]. Group 5: Strategic Positioning - Jianfa Zhixin is adapting to changes in the economic environment and healthcare reforms by transforming hospital procurement departments from profit centers to cost centers, emphasizing the need for efficient medical supply chain capabilities [7]. - The company aims to create a win-win ecosystem by integrating upstream and downstream resources, establishing long-term partnerships with manufacturers, and achieving digital and transparent procurement processes [7].